Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Allergy|June 13, 2017
What's in a name? Atopic dermatitis or atopic eczema, but not eczema aloneJ I Silverberg, J P Thyssen, A S Paller, et al.
Scandinavian Journal of Immunology|September 30, 2008
CD8+CD60+ T cells, cells expressing epsilon specific mRNA and Th1/Th2 cytokines in cord blood and at 7 months of ageT A Smith-Norowitz, K B Norowitz, J I Silverberg, et al.
The British Journal of Dermatology|January 17, 2018
Systematic review of atopic dermatitis disease definition in studies using routinely collected health dataM P Dizon, A M Yu, R K Singh, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 16, 2024
Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMENJ P Thyssen, J I Silverberg, J Ruano, et al.
The Journal of Dermatological Treatment|April 30, 2020
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trialsS Barbarot, A Wollenberg, J I Silverberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 4, 2020
Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitisJ I Silverberg, D Lei, M Yousaf, et al.
The British Journal of Dermatology|April 30, 2020
Measurement properties of the Rajka-Langeland severity score in children and adults with atopic dermatitisJ I Silverberg, D Lei, M Yousaf, et al.
The British Journal of Dermatology|September 22, 2020
What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational studyJ I Silverberg, D Lei, M Yousaf, et al.
The British Journal of Dermatology|October 1, 2020
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trialJ I Silverberg, D Toth, T Bieber, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 12, 2021
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B studyJ I Silverberg, A Pinter, A Alavi, et al.
Pageof 7